OlympiA, a phase III clinical trial, comprised 1836 early breast cancer patients carrying a pathogenic BRCA1/2 variant with TNBC or hormone receptor-positive HER2-negative breast cancer and compared 1 year of olaparib versus a placebo [137]. Here, ERBB2 is linked to breast carcinoma.